Nuochengjianhua announced on October 13 that the novel BCL2 inhibitor metocla combined with obutinib independently developed by the company to treat relapsed/refractory marginal lymphoma has been approved by the Drug Evaluation Center of the China Drug Administration to conduct a phase III clinical trial. This is the fifth registered clinical trial approved by Metocla.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.